I agree that this site is using cookies. You can find further informations here.
X
Peng, Stanford L.
134  results:
Search for persons X
?
1

WCN24-756 POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGON..:

Tumlin, James ; Mandayam, Sreedhar ; Madan, Arvind...
Kidney International Reports.  9 (2024)  4 - p. S141 , 2024
Link: https://doi.org/10.1016/..
 
?
2

WCN24-762 UPDATED RESULTS FROM THE RUBY-3 STUDY OF POVETACI..:

Tumlin, James ; Mandayam, Sreedhar ; Madan, Arvind...
Kidney International Reports.  9 (2024)  4 - p. S505 , 2024
Link: https://doi.org/10.1016/..
 
?
3

#1342 Updated results from the RUBY-3 study of povetacicept..:

Madan, Arvind ; Park, Inwhee ; Yalavarthy, Rajesh...
Nephrology Dialysis Transplantation.  39 (2024)  Supplement_1 - p. , 2024
Link: https://doi.org/10.1093/..
 
?
4

Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That M..:

Evans, Lawrence S. ; Lewis, Katherine E. ; DeMonte, Daniel...
Arthritis & Rheumatology.  75 (2023)  7 - p. 1187-1202 , 2023
Link: https://doi.org/10.1002/..
 
?
5

#4024 PHASE 1 STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKI..:

Dilllon, Stacey ; Davies, Rupert ; Lickliter, Jason...
Nephrology Dialysis Transplantation.  38 (2023)  Supplement_1 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
6

42273 Phase 1 Study in Healthy Adults of the Safety, Tolera..:

Dillon, Stacey R. ; Davies, Rupert H. ; Lickliter, Jason D....
Journal of the American Academy of Dermatology.  89 (2023)  3 - p. AB74 , 2023
Link: https://doi.org/10.1016/..
 
?
7

PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE..:

Broome, Catherine M ; Arnold, Donald ; Piatek, Caroline...
HemaSphere.  7 (2023)  S3 - p. e691820b , 2023
Link: https://doi.org/10.1097/..
 
?
8

S276: POVETACICEPT (ALPN-303), A POTENT DUAL BAFF/APRIL ANT..:

Dillon, Stacey ; Davies, Rupert ; Lickliter, Jason...
HemaSphere.  7 (2023)  S3 - p. e3301055 , 2023
Link: https://doi.org/10.1097/..
 
?
9

Non‐Redundant Roles of T Cell Costimulation Pathways in Inf..:

Dillon, Stacey R. ; Evans, Lawrence S. ; Lewis, Katherine E....
Arthritis & Rheumatology.  75 (2023)  8 - p. 1344-1356 , 2023
Link: https://doi.org/10.1002/..
 
?
10

The engineered CD80 variant fusion therapeutic davoceticept..:

Maurer, Mark F. ; Lewis, Katherine E. ; Kuijper, Joseph L....
Nature Communications.  13 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
11

First‐in‐human study of the safety, tolerability, pharmacok..:

Yang, Jing ; Lickliter, Jason D. ; Hillson, Jan L....
Clinical and Translational Science.  14 (2021)  4 - p. 1314-1326 , 2021
Link: https://doi.org/10.1111/..
 
?
12

Alpn-101 (ICOSL vIgD-Fc), a Dual Antagonist of the ICOS and..:

Ramakrishnan, Aravind ; Woolfrey, Ann ; Hillson, Jan...
Transplantation and Cellular Therapy.  27 (2021)  3 - p. S265-S266 , 2021
Link: https://doi.org/10.1016/..
 
?
13

Le Relapsing Polychondritis Damage Index (RPDAM) : développ..:

Mertz, Philippe ; Belot, Alexandre ; Cervera, Ricard...
Revue du Rhumatisme.  87 (2020)  2 - p. 122-127 , 2020
Link: https://doi.org/10.1016/..
 
?
14

Mo1093 ALPN-101, A FIRST-IN-CLASS DUAL ICOS/CD28 ANTAGONIST..:

Dillon, Stacey R. ; Evans, Lawrence S. ; Bort, Susan...
Gastroenterology.  158 (2020)  6 - p. S-786 , 2020
Link: https://doi.org/10.1016/..
 
?
15

Novel Immunomodulatory Proteins Generated via Directed Evol..:

Levin, Steven D. ; Evans, Lawrence S. ; Bort, Susan...
Frontiers in Immunology.  10 (2020)  - p. , 2020
Link: https://doi.org/10.3389/..
 
1-15